HC Wainwright Has Positive Estimate for ZNTL Q2 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Analysts at HC Wainwright upped their Q2 2026 earnings per share estimates for shares of Zentalis Pharmaceuticals in a note issued to investors on Wednesday, May 13th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.52) for the quarter, up from their prior estimate of ($0.54). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($1.94) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at ($0.60) EPS and FY2026 earnings at ($2.19) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01).

A number of other research firms have also weighed in on ZNTL. Wall Street Zen lowered Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Wells Fargo & Company initiated coverage on Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Tuesday, April 7th. Finally, Guggenheim lifted their price target on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $5.00.

Zentalis Pharmaceuticals Stock Performance

NASDAQ ZNTL opened at $4.09 on Friday. The stock has a 50-day simple moving average of $3.47 and a two-hundred day simple moving average of $2.49. The firm has a market capitalization of $291.15 million, a P/E ratio of -2.36 and a beta of 1.99. Zentalis Pharmaceuticals has a fifty-two week low of $1.13 and a fifty-two week high of $6.95.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Sei Investments Co. increased its stake in shares of Zentalis Pharmaceuticals by 14.6% in the 1st quarter. Sei Investments Co. now owns 191,551 shares of the company’s stock valued at $448,000 after purchasing an additional 24,451 shares in the last quarter. State of Wyoming acquired a new stake in Zentalis Pharmaceuticals in the 1st quarter worth about $67,000. Dimensional Fund Advisors LP boosted its holdings in Zentalis Pharmaceuticals by 182.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 272,034 shares of the company’s stock worth $634,000 after buying an additional 175,771 shares during the last quarter. Private Advisor Group LLC acquired a new stake in Zentalis Pharmaceuticals in the 1st quarter worth about $74,000. Finally, Invesco Ltd. boosted its holdings in Zentalis Pharmaceuticals by 8.6% in the 4th quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock worth $255,000 after buying an additional 14,961 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.